A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
Market Scope
Trusted Global Partner of Industry and Medical Professionals for Ophthalmic Market Research, Primary Research, Independent Perspective, & Objective Analysis
Choose Your Experience
Over 500 Clients, Large & Small from Around the World, Trust Market Scope Data & Analysis
Latest Market Reports
Market Scope's industry reports are meticulously prepared by a dedicated team of in-house consultants/analysts with over 100 years of collective experience.
- 269
Comprehensive Pages
- 8
Geographic and Economic Breakouts
- 5
Year Market Forecasts
- 52
Diseases Analyzed
2025 Cornea Products Market Report: Global Analysis for 2024 to 2030, December, 2025
The “2025 Cornea Products Market Report” delivers an in-depth analysis of the global cornea market, highlighting the latest advances in transplantation, crosslinking, and therapeutic devices aimed at restoring and preserving vision. The report estimates disease prevalence across six major corneal conditions and examines evolving treatment approaches, including cornea transplants, therapeutic lenses, phototherapeutic keratectomy (PTK), intrastromal ring segments, and corneal crosslinking.
It also explores the global ecosystem that supports cornea care—spanning organ donation systems, regulatory environments, and the pivotal roles of cornea specialists, eye banks, and nonprofit organizations.
This 2025 edition evaluates more than 70 products from over 50 companies, with forecasts for unit demand and revenue growth through 2030. It features analysis of emerging pipeline technologies yet to generate revenue and profiles 12 leading market participants shaping the future of cornea treatment.
Latest Industry News & Trends
6/12/2026
BreakingChinaDealsPresbyopia
Everest Acquires Rights in Greater China to Lenz’ Vizz for Presbyopia
Everest Medicines, of Shanghai, China, has acquired rights in Greater China to Lenz Therapeutics’ Vizz (LNZ100) eye drops for presbyopia, Lenz reported June 7. Lenz, of San Diego, California, said ...
6/12/2026
BiosimilarsBreakingEuropeRetina
Formycon’s Aflibercept Biosimilar in Prefilled Syringes Now Available in EU
Germany’s Formycon announced May 19 that its aflibercept (Eylea) biosimilar, known in various territories as Ahzantive and Baiama, was now available in the European Union. It is being introduced in...
6/12/2026
BiosimilarsBreakingEuropeRetina
Samsung Bioepis Launches Aflibercept Biosimilar Branded Opuviz in EU
Korea’s Samsung Bioepis announced May 29 that it had launched Opuviz, a biosimiliar referencing Eylea (aflibercept), across Europe. The biosimilar is also available in Korea and Canada as Aflivu. H...
6/12/2026
AllergyBreakingDry EyePharma
Harrow Relaunches Verkazia in the US for Vernal Keratoconjunctivitis
Harrow reported June 10 that it had relaunched Verkazia (cyclosporine ophthalmic emulsion, 0.1%) in the US for the treatment of vernal keratoconjunctivitis (VKC). VKC is a serious allergic eye dise...
6/12/2026
AIBreakingDealsDigital
AAO Licenses Clinical Practice Guidelines to OpenEvidence Chatbot for Doctors
The American Academy of Ophthalmology reported June 9 that it had licensed the guidance in itsPreferred Practice Patterns and Ophthalmic Technology Assessments to OpenEvidence for its medical AI pl...
6/12/2026
BreakingCataractPharmaRegulation
Apotex Gains Health Canada Approval for Iheezo Ophthalmic Anesthesia
Toronto’s Apotex announced May 26 that it had secured Health Canada marketing approval for Iheezo (chloroprocaine hydrochloride ophthalmic gel 3%), a topical anesthetic indicated for ocular surface...
6/12/2026
BreakingDry Eye
Bausch + Lomb Launches Blink Triple Care Preservative Free Drops in US
Bausch + Lomb announced June 1 the US launch of Blink Triple Care Preservative Free eye drops. The lipid- and water-based formula combines a natural oil—to help keep tears from evaporating too quic...
6/12/2026
BiosimilarsBreakingRegulationRetina
Lupin Gains US FDA Approval for Ranibizumab Biosimilar Branded Ranluspec
India’s Lupin Limited announced June 4 that the US FDA had approved Ranluspec (ranibizumab-hkdz) as an interchangeable biosimilar referencing Lucentis. Lupin said Ranluspec was the only interchange...
Provider Surveys & Interviews
Grab a seat at the table and join the thousands of ophthalmologists and optometrists from over 60 countries who are helping shape the next generation of diagnostics, pharmaceuticals, devices, and equipment by sharing your opinion and experience. Make your voice heard!
Choose Your Own Adventure
Participation options include weekly polls, special sponsored surveys, syndicated quarterly surveys, focus groups, and interviews, each with varying levels of honoraria.
Safe, Secure & On Any Device
We follow all industry standards to ensure confidentiality between participants and clients. Start and stop surveys anytime on our free Market Scope+ App or on desktop, each with a personalized dashboard just for you.
Pre-Qualified Invitations
We individually verify all potential participants before each survey or interview, ensuring that only licensed eye care professionals are invited and they are never kicked out or disqualified.
Better Data = Better Decisions
A team of industry experts and analysts review each data point, so you can be confident in the results and trends provided in our reports.
Download the Market Scope+ app to get started!
Market Scope Methodology
A Multi-Step Approach for Accurate & Timely Data
Proprietary data
- 20+ years of physician survey data
- Disease models
- Cultivated database of physicians, ASCs, and hospitals
- Insight from our team of in-house industry experts
Public data
- Attendance and participation at major, worldwide meetings
- Public health systems and registries
- Clinical study data
- Analysis of company-published financial reports
Join Market Scope Today
Register A Corporate Account
Register A Clinical Account
A clinical account gives you access to survey participation and results, weekly polls, benchmark reports, a searchable news archive, and more on a personalized dashboard.